Covista: Chamberlain Turns, AI Takes the Wheel – A Rebrand with Teeth

ATGE's fiscal Q3 shows enrollment recovery, raised guidance, and a pivot toward AI-powered healthcare education under the new Covista banner.

ATGE · Earnings Call · 2026-05-08

Introduction: A Pivot Wrapped in a Rebrand

A company that has spent a decade as Adtalem Global Education is now Covista, a name that signals a deliberate shift from a holding company to a unified platform for healthcare workforce development. The fiscal Q3 2026 results, reported on May 8, 2026, clearly show why the rebrand carries substance: revenue grew 4.5% to $487 million (or 8.4% excluding a one-week calendar shift), adjusted EPS guidance was raised for the second straight quarter, and Chamberlain University—the flagship nursing school—returned to positive total enrollment growth a quarter earlier than promised. CEO Stephen Beard captured the strategic intent: “The name reflects what we've been building, a single platform for health care workforce development on a national scale, backed by the performance you're seeing in this quarter's results.” — Stephen Beard, Chairman and Chief Executive Officer · 2026-05-08

Chamberlain: From Misstep to Turnaround

The most critical narrative is Chamberlain's recovery. A year ago, the company admitted an execution miss in its marketing and enrollment funnel, leading to a deceleration in post-licensure nursing enrollments. In prior calls, Beard insisted the issue was internal, not competitive: “So again, this is not a trend that has legs. This is a onetime dislocation that's a result of our execution miss.” — Stephen Beard, Chairman and Chief Executive Officer · 2025-10-30 That confidence is now paying off. In Q3 FY2026, Chamberlain returned to positive total enrollment growth (0.5% year-over-year to 40,767 students), marking the 15th consecutive quarter of pre-licensure growth and the highest enrollment in university history. Beard was careful not to overclaim: “We're not declaring victory on a single quarter of 0.5% enrollment growth, but we are telling you that the operating model is working and the trajectory ahead is stronger than the trailing numbers suggest.” — Stephen Beard, Chairman and Chief Executive Officer · 2026-05-08 The leading indicators support that view: application volumes are up double digits, and conversion rates have normalized. When asked whether the Q4 growth rate will match Q3, Beard replied: “We expect the rate of growth to be directionally similar.” — Stephen Beard, Chairman and Chief Executive Officer · 2026-05-08

Walden Compounding, Med/Vet Margin Discipline

Walden University continues to be the compounding machine, growing total enrollment 12.3% to a record 54,474 students, its 11th consecutive quarter of growth. Excluding the one-week calendar shift, Walden's revenue would have increased 14.7% and adjusted EBITDA margin would have expanded 280 basis points to 33.1%. The Medical and Veterinary segment delivered 8.9% revenue growth and a 250-basis-point adjusted EBITDA margin expansion to 26.5%, driven by both medical and veterinary programs. This is a quality story: the company has been investing in student persistence (a form of customer success), which quietly compounds retention and economics.

Rebranding to Covista: AI and Workforce Development

The rebrand to Covista is not cosmetic; it aligns with a renewed focus on technology and employer integration. The company is codeveloping an AI-powered classroom with Google Cloud, and has already enrolled over 4,000 learners in newly launched AI credentials across nursing, medicine, and foundational AI. Beard described the vision:

The goal is a personalized learning companion that supports each student from first course to graduation.
Stephen Beard, Chairman and Chief Executive Officer · 2026-05-08

This is a direct answer to the structural healthcare labor shortage—700,000 healthcare jobs posted monthly with only 306,000 unemployed healthcare workers to fill them. The company's scale gives it an edge: 5 institutions, 24,000 graduates annually, and deep clinical relationships. The brand campaign for Chamberlain is expected to compound through fiscal 2027, directly supporting Brand awareness. The AI initiative, meanwhile, taps into the broader market theme of artificial intelligence applications—a trend that is resonating across industries.

Financial Strength and Capital Allocation

The financial engine underlying all this is sturdy. Revenue guidance for the full year was raised to $1.93–$1.945 billion, implying 8–9% growth, while adjusted EPS guidance was boosted to $7.95–$8.15, up from $7.80–$8.00, a 19–22% increase year-over-year. CFO Robert Phelan noted: “Excluding the 1-week timing impact, consolidated revenue would have increased 8.4% year-over-year, and adjusted EBITDA would have increased 14.2%.” — Robert Phelan, Chief Financial Officer · 2026-05-08 This earnings growth is supported by operational leverage and disciplined investment. The balance sheet is in great shape: net leverage is just 0.7x, and the company refinanced its long-term debt, cutting 50 basis points off rates and extending maturity to 2033. It repurchased $66 million of stock during the quarter, signaling confidence in intrinsic value. Free cash flow (trailing 12-month) grew 17% to $336 million. Revenue increased 4.5% to $487 million, but excluding the one-week Walden calendar shift, growth was 8.4%–a clear indication of the underlying trajectory. The prior call in January had already flagged that the company would invest in strategic growth in the fourth quarter, and that remains the case. But the raised guidance speaks to the confidence in the underlying momentum. The rebrand is a bet on scale and integration, and the numbers so far suggest the bet is paying off. As Beard put it, "Purpose at scale is not a plan we're about to roll out; it's an extension of the operating model that's already producing this quarter's results." For now, investors seem to agree: the stock has risen 37% over the trailing 90 days, and the market is listening.